OPT-In; Optimized Patient Treatment Outcomes in Plaque Psoriasis: A 3-Year State-Transition Treatment-Sequencing Model in the Italian Setting

Overview

Journal Dermatol Ther (Heidelb)

Date 2024 May 10

PMID 38727995

Authors

Sarah Alulis

Nicoletta Bernardini

Martina Burlando

Antonio Costanzo

Pier Cesare Francesa Morel

Paolo Gisondi

Francesco Loconsole

Matteo Megna

Giovanni Pellacani

Stefano Piaserico

Francesca Prignano

Ottavio Secchi

Nevena Skroza

Fareen Hassan

Affiliations

Soon will be listed here.

Abstract

Introduction: There are several treatment options for plaque psoriasis (PsO), but uncertainty remains around the optimal sequencing of treatments. The aims of this study were to investigate how adopting a best-treatment-first treatment sequence impacts patient outcomes and healthcare systems and to quantify the cost of treatment failure to the healthcare system.

Methods: A 3-year state-transition treatment-sequencing model which identifies all possible treatment sequences in PsO was adapted to the Italian healthcare setting. Treatments considered in the model are those with European Medicines Agency marketing authorization and reimbursement in Italy as of December 2022. Italian market share data (2019-2021) and list prices (2022) informed the current prescribed sequences; these sequences were compared against all possible sequences to determine opportunities for improvement. Both the national perspective in Italy as well as the local perspective from seven regions were considered. The cost of treatment failure was informed through a questionnaire circulated to Italian dermatologists.

Results: Overall, 1284 possible treatment sequences are possible when four lines of treatment are considered for patients with moderate-to-severe PsO in Italy. Within the estimated range of treatment failures across those sequences (0.97-2.56 per patient over 3 years), current prescribing behavior from the national perspective suggests patients will face 1.44 failures on average; this highlights the potential for improvement. For every treatment failure, the cost borne by the Italian National Healthcare Service (NHS) is €676.80. Overall, prescribing more optimized treatment sequences results in a 22.95% reduction in failures with a 2.27% increase in costs. The regional analyses found similar trends.

Conclusions: Results suggest that selecting the most effective treatment sequences for incident patients provides the greatest opportunity to reduce treatment failures and maximize patient outcomes with a modest impact on costs. While regional variations exist, there is room for improvement across the board, which could translate to more efficient local healthcare systems.

References

Hart R, Hassan F, Alulis S, Patterson K, Barthelmes J, Boer J . Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes. Adv Ther. 2024; 41(5):2010-2027. PMC: 11052888. DOI: 10.1007/s12325-023-02766-w. View

Armstrong E, Harskamp C, Armstrong A . Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013; 2(2):e000062. PMC: 3647278. DOI: 10.1161/JAHA.113.000062. View

Blauvelt A, Papp K, Griffiths C, Randazzo B, Wasfi Y, Shen Y . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active.... J Am Acad Dermatol. 2017; 76(3):405-417. DOI: 10.1016/j.jaad.2016.11.041. View

Holmen Moller A, Erntoft S, Vinding G, Jemec G . A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas. 2015; 6:167-77. PMC: 4500621. DOI: 10.2147/PROM.S81428. View

Dalgard F, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec G . The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2014; 135(4):984-991. PMC: 4378256. DOI: 10.1038/jid.2014.530. View

Reich K, Armstrong A, Foley P, Song M, Wasfi Y, Randazzo B . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III,.... J Am Acad Dermatol. 2017; 76(3):418-431. DOI: 10.1016/j.jaad.2016.11.042. View

Hjuler K, Bottcher M, Vestergaard C, Deleuran M, Raaby L, Botker H . Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. Am J Med. 2015; 128(12):1325-34.e2. DOI: 10.1016/j.amjmed.2015.05.041. View

Bardazzi F, Bonci C, Sacchelli L, DI Altobrando A, Iommi M, Rucci P . Suicide risk and depression in patients with psoriasis. Ital J Dermatol Venerol. 2023; 157(6):497-501. DOI: 10.23736/S2784-8671.22.07184-5. View

Bellinato F, Chiricozzi A, Piaserico S, Targher G, Gisondi P . Could Targeted Pharmacotherapies Exert a "Disease Modification Effect" in Patients with Chronic Plaque Psoriasis?. Int J Mol Sci. 2022; 23(21). PMC: 9658165. DOI: 10.3390/ijms232112849. View

10.

Cohen A, Dreiher J, Birkenfeld S . Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009; 23(5):561-5. DOI: 10.1111/j.1468-3083.2008.03031.x. View

11.

Parisi R, Symmons D, Griffiths C, Ashcroft D . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2012; 133(2):377-85. DOI: 10.1038/jid.2012.339. View

12.

Alinaghi F, Calov M, Kristensen L, Gladman D, Coates L, Jullien D . Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2018; 80(1):251-265.e19. DOI: 10.1016/j.jaad.2018.06.027. View

13.

Kurd S, Troxel A, Crits-Christoph P, Gelfand J . The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010; 146(8):891-5. PMC: 2928071. DOI: 10.1001/archdermatol.2010.186. View

14.

Dowlatshahi E, Wakkee M, Arends L, Nijsten T . The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2013; 134(6):1542-1551. DOI: 10.1038/jid.2013.508. View

15.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L . Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015; 373(14):1318-28. DOI: 10.1056/NEJMoa1503824. View

16.

Masson Regnault M, Konstantinou M, Khemis A, Poulin Y, Bourcier M, Amelot F . Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017; 31(9):1491-1496. DOI: 10.1111/jdv.14387. View

17.

Ikumi K, Odanaka M, Shime H, Imai M, Osaga S, Taguchi O . Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice. J Invest Dermatol. 2019; 139(6):1329-1338.e7. DOI: 10.1016/j.jid.2019.01.029. View

18.

Guerriero F, Orlando V, Monetti V, Russo V, Menditto E . Biological therapy utilization, switching, and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy. Clinicoecon Outcomes Res. 2017; 9:741-748. PMC: 5716306. DOI: 10.2147/CEOR.S147558. View

19.

Lunder T, Zorko M, Kolar N, Suhodolcan A, Marovt M, Leskovec N . Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019; 58(6):631-641. DOI: 10.1111/ijd.14429. View

20.

Rodriguez-Zuniga M, Garcia-Perdomo H . Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017; 77(4):657-666.e8. DOI: 10.1016/j.jaad.2017.04.1133. View